EMA Management Board: highlights of June 2026 meeting
Submitted by Anonymous (not verified) on 15 June 2026 - 10:20
EMA Management Board: highlights of June 2026 meeting
Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan, sitagliptin hydrochloride monohydrate,metformin hydrochloride, Date of authorisation: 16/02/2022, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 15 June 2026 - 9:40
Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan, sitagliptin hydrochloride monohydrate,metformin hydrochloride, Date of authorisation: 16/02/2022, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Tadalafil Mylan, tadalafil, Date of authorisation: 21/11/2014, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 15 June 2026 - 9:38
Human medicines European public assessment report (EPAR): Tadalafil Mylan, tadalafil, Date of authorisation: 21/11/2014, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 15 June 2026 - 8:44
Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Zutectra, human hepatitis B immunoglobulin, Date of authorisation: 30/11/2009, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 12 June 2026 - 15:32
Human medicines European public assessment report (EPAR): Zutectra, human hepatitis B immunoglobulin, Date of authorisation: 30/11/2009, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 12 June 2026 - 15:25
Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 18, Status: Authorised
Lonquex : EPAR - Public assessment report
Submitted by Anonymous (not verified) on 12 June 2026 - 15:12
Lonquex : EPAR - Public assessment report
Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 12 June 2026 - 15:11
Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz,emtricitabine,tenofovir disoproxil, Date of authorisation: 05/09/2017, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 12 June 2026 - 14:55
Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz,emtricitabine,tenofovir disoproxil, Date of authorisation: 05/09/2017, Revision: 19, Status: Authorised
Products Management Services (PMS) public API - Terms and conditions
Submitted by Anonymous (not verified) on 12 June 2026 - 14:54
Products Management Services (PMS) public API - Terms and conditions